Evidence map›Paper›PMID 22064677›Full record

ArticleMolecular pharmacology2012

Specificity determinants of allosteric modulation in the neuronal nicotinic acetylcholine receptor: a fine line between inhibition and potentiation.

Laura C Cesa, Colin A Higgins, Steven R Sando, Dennis W Kuo, Mark M Levandoski

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Tetrapeptide Ac-HAEE-NHInternational journal of molecular sciences · 2020
    Article
  3. Potentiation of a neuronal nicotinic receptor via pseudo-agonist site.Cellular and molecular life sciences : CMLS · 2019
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Laura C CesaDepartment of Chemistry, Grinnell College, Grinnell, Iowa, USA.
Colin A Higgins
Steven R Sando
Dennis W Kuo
Mark M Levandoski
Grinnell College · US

Funding

Allosteric Potentiation of Neuronal Nicotinic ReceptorsR15NS070760 · NINDS · GRINNELL COLLEGE · PI LEVANDOSKI, MARK M · 2010 to 2010
$374k
Howard Hughes Medical Institute 52006298NINDS NIH HHS 1R15-NS070760-01NINDS NIH HHS R15 NS070760
6 · The paper itself

Abstract

We are interested in the allosteric modulation of neuronal nicotinic acetylcholine receptors (nAChRs). We have postulated that the anthelmintic morantel (Mor) positively modulates (potentiates) rat α3β2 receptors through a site located at the β(+)/α(-) interface that is homologous to the canonical agonist site (J Neurosci 29:8734-8742, 2009). On this basis, we aimed to determine the site specificity by studying differences in modulation between α3β2 and α4β2 receptors. We also compared modulation by Mor with that of the related compound oxantel (Oxa). Whereas Mor and Oxa each potentiated α3β2 receptors 2-fold at saturating acetylcholine (ACh) concentrations, Mor had no effect on α4β2 receptors, and Oxa inhibited ACh-evoked responses. The inhibition was noncompetitive, but not due to open channel block. Furthermore, the nature and extent of modulation did not depend on subunit stoichiometry. We studied six positions at the α(-) interface that differ between α3 and α4. Two positions (α3Ile57 and α3Thr115) help mediate the effects of the modulators but do not seem to contribute to specificity. Mutations in two others (α3Leu107 and α3Ile117) yielded receptors with appreciable α4-character; that is, Mor potentiation was reduced compared with wild-type α3β2 control and Oxa inhibition was evident. A fifth position (α3Glu113) was unique in that it discriminated between the two compounds, showing no change in Mor potentiation from control but substantial Oxa inhibition. Our work has implications for rational drug design for nicotinic receptors and sheds light on mechanisms of allosteric modulation in nAChRs, especially the subtle differences between potentiation and inhibition.

Indexed as

Allosteric SiteDrug DesignAllosteric RegulationAnimalsAnthelminticsMorantelMutationNicotinic AgonistsNicotinic AntagonistsProtein SubunitsPyrantelRatsReceptors, NicotinicAnthelminticsMorantelNicotinic AgonistsNicotinic AntagonistsoxantelProtein SubunitsPyrantelReceptors, Nicotinic

Identifiers

PMID22064677
PMCPMC3263947
OpenAlexW2121189786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.